Global Information
회사소개 | 문의

심근경색 : 파이프라인 리뷰

Myocardial Infarction - Pipeline Review, H2 2018

리서치사 Global Markets Direct
발행일 2018년 08월 상품 코드 229746
페이지 정보 영문 279 Pages
가격
US $ 2,000 ₩ 2,296,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,592,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 6,888,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


심근경색 : 파이프라인 리뷰 Myocardial Infarction - Pipeline Review, H2 2018
발행일 : 2018년 08월 페이지 정보 : 영문 279 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

한글목차

심근경색(또는 심장허혈)은 심근에 대한 혈류·산소 공급이 부족한 경우에 발생합니다. 주요 징후·증상으로 흉통(특히 인체의 좌측/협심증)을 비롯하여 경부·턱의 통증, 어깨·팔의 통증, 식은 땀, 호흡 곤란, 구역질·구토 등을 들 수 있습니다. 또한 관상동맥 질환(아테로마 경화증) 및 혈전, 관혈관 연축, 기타 중병이 원인으로 발병하는 경우도 있습니다. 발증 리스크의 증대 요인으로 흡연 및 당뇨병, 고혈압, 고콜레스테롤혈증(고트리글리세리드혈증), 운동부족, 비만, 가족력 등이 있습니다.

세계 각국에서의 심근경색 치료용 파이프라인 제품의 개발 상황에 대해 분석했으며, 제품 개발·출시의 최신 동향, 임상시험 각 단계의 제품 리스트, 주요 기업의 개요, 주요 약제 개요, 최신 업계 동향 등의 정보를 정리하여 전해드립니다.

목차

서론

  • 분석 범위

심근경색의 개요

치료제 개발

  • 심근경색용 파이프라인 제품 : 개요
  • 심근경색용 파이프라인 제품 : 비교 분석

각 기업에서 개발중인 심근경색 치료제

대학/연구기관에서 연구중인 심근경색 치료제

파이프라인 제품의 개요

  • 후기 단계 제품
  • 임상시험 단계 제품
  • 초기 단계 제품
  • 불명확한 단계에 있는 제품

심근경색 치료제 : 개발중인 제품 리스트(기업별)

심근경색 치료제 : 연구중인 제품 리스트(대학/연구기관별)

심근경색 치료제 개발에 참여하고 있는 기업

  • Amarantus Bioscience Holdings, Inc.
  • Angion Biomedica Corp.
  • Asterias Biotherapeutics, Inc.
  • AstraZeneca Plc
  • Athersys, Inc.
  • Bayer AG
  • Bharat Biotech International Limited
  • BioCardia, Inc.
  • Biscayne Pharmaceuticals, Inc.
  • Capricor Therapeutics, Inc.
  • CellProthera
  • Celyad SA
  • Compugen Ltd.
  • CSL Limited
  • Cynata Therapeutics Limited
  • FibroGen, Inc.
  • Hemostemix Ltd
  • Human Stem Cells Institute
  • HUYA Bioscience International, LLC
  • Immune Pharmaceuticals Inc.
  • Juventas Therapeutics, Inc.
  • Laboratoires Pierre Fabre SA
  • Lee's Pharmaceutical Holdings Limited
  • LegoChem Biosciences, Inc
  • LG Life Science LTD.
  • Medestea Research & Production S.p.A.
  • Mesoblast Limited
  • miRagen Therapeutics, Inc.
  • Moderna Therapeutics, Inc.
  • MorphoSys AG
  • NeuroVive Pharmaceutical AB
  • New World Laboratories, Inc.
  • Novartis AG
  • Omeros Corporation
  • Omeros Corporation
  • Pfizer Inc.
  • Polyphor Ltd.
  • Primary Peptides, Inc.
  • Quantum Genomics SA
  • Quark Pharmaceuticals, Inc.
  • Recardio GmbH
  • Serodus ASA
  • Silver Creek Pharmaceuticals, Inc.
  • Stealth BioTherapeutics Inc.
  • Stemedica Cell Technologies, Inc.
  • Stempeutics Research Private Limited
  • TaiGen Biotechnology Co., Ltd.
  • Targazyme, Inc.
  • The International Biotechnology Center(IBC) Generium
  • TiGenix NV
  • Vicore Pharma AB
  • XBiotech USA, Inc.
  • Yuyu Pharma, Inc.
  • Zydus Cadila Healthcare Limited

심근경색 : 치료제 평가

  • 단일요법 치료제의 경우
  • 병용 치료제의 경우
  • 표적별
  • 작용기서별
  • 투여 방법별
  • 분자 종류별

약제 개요

  • (sacubitril + valsartan)
  • AB-002
  • ACP-01
  • Alda-1
  • 알테프라제(혈전 용해제) 바이오시밀러
  • AMRS-001
  • ANG-4011
  • 심근경색용 miR-92 저해 안티센스 RNAi 올리고뉴클레오티드
  • AP-102
  • APO-1
  • balixafortide
  • 류마티스 관절염·급성 심근경색·염증성 질환용 바이오시밀러 3
  • BIS-5409
  • bococizumab
  • burixafor
  • C-21
  • C3BSGQR-3
  • C3BSGQR-4
  • CAP-1001
  • CAP-1002
  • cenderitide
  • CGEN-856S
  • CIGB-500
  • CM-1
  • Cryocell
  • CSL-112
  • CTX-101
  • cyclosporine
  • 순환기 질환용 Alpha Myosin 저해제
  • 허혈성 뇌졸중·심근경색용 SIRT2 저해제
  • dutogliptin tartrate
  • elamipretide
  • 심근경색용 에프린 A-1
  • F-573
  • FG-6874
  • Gemacell
  • 급성 심근경색용 유전자 요법
  • HBI-3802
  • HYPER-IL-6
  • ICG-001
  • IS-20
  • JI-38
  • JVS-100
  • JVS-200
  • KR-33028
  • LC-280126
  • LWnt-3a
  • Lysimab
  • MGN-1374
  • MGN-6114
  • MIF-2
  • MIF-20
  • 심근경색·죽상동맥경화증용 IL-1 a 저해 모노클로널 항체
  • 심근경색용 만노오스 수용체 표적 모노클로널 항체 복합체
  • MPC-150IM
  • MPC-25IC
  • Neu-2000
  • NP-202
  • NVP-019
  • NVX-308
  • NWL-53
  • 종양학·심장혈관용 올리고뉴클레오티드
  • 순환기 질환·신장 질환용 올리고뉴클레오티드
  • OMS-721
  • OPC-28326
  • 순환기 질환·대사장애·발기부전용 Mas 관련 G단백질 연결 수용체 활성 펩티드
  • 당뇨병·심부전용 아펠린 수용체 작동 펩티드
  • PF-05285401
  • 급성 심근경색용 Polyglactin 370
  • PP-001
  • 심근경색·중증하지허혈용 LRP5/LRP6 작동 단백질
  • ProtheraCytes
  • QGC-101
  • QPCP-1
  • RBB-001
  • 순환기 질환용 재조합단백질
  • 심근경색용 재조합단백질질
  • 심근경색용 IGF-1 R 작동 재조합단백질
  • 재조합 프로우로키나아제
  • remestemcel-L
  • rivaroxaban
  • 심근경색용 RNAi 올리고뉴클레오티드
  • salicylamine
  • SER-130
  • 심근경색용 소분자
  • 재관류 손상·심장마비용 소분자
  • CAHD·뇌졸중용 혈액 인자 XIa 저해제
  • 심근경색·염증성 질환용 소분자
  • 천식·심근경색용 아데노신 A2B 수용체 길항제
  • 심근경색용 저해제 BAX
  • 심근경색용 저해제 MMP
  • 면역학·종양학·순환기 질환·대사장애용 PARP 저해제
  • 순환기 질환용 PDE5 저해제
  • 산화적 스트레스 관련 질환용 유리기 제거 소분자
  • 급성 심근경색용 줄기세포 요법
  • 순환기 질환용 줄기세포 요법
  • 순환기 질환·중추신경 장애·대사장애·호흡기질환·염증성 질환·독물학용 줄기세포 요법
  • 순환기 질환용 줄기세포 요법
  • 심근경색·심부전용 줄기세포 요법
  • Stempeucel
  • 순환기 질환용 에리스로포이에틴(적혈구 생성 촉진인자) 수용체 활성 합성 펩티드
  • TF-0023
  • THR-100
  • ticagrelor
  • TZ-101
  • VN-100
  • ZK-001

심근경색 치료제 : 파이프라인 제품의 최신 동향

심근경색 치료제 : 개발 휴지 상태의 제품

심근경색 치료제 : 개발이 중지된 제품

심근경색 관련 제품의 개발 마일스톤

  • 주목해야 할 최신 동향·프레스 릴리스

부록

도표

KSA 16.06.02

List of Tables

  • Number of Products under Development for Myocardial Infarction, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products under Development by Universities/Institutes, H2 2018
  • Products under Development by Companies, H2 2018
  • Products under Development by Universities/Institutes, H2 2018
  • Number of Products by Stage and Target, H2 2018
  • Number of Products by Stage and Mechanism of Action, H2 2018
  • Number of Products by Stage and Molecule Type, H2 2018
  • Myocardial Infarction - Pipeline by Actinogen Medical Ltd, H2 2018
  • Myocardial Infarction - Pipeline by Angion Biomedica Corp, H2 2018
  • Myocardial Infarction - Pipeline by Athersys Inc, H2 2018
  • Myocardial Infarction - Pipeline by Bharat Biotech Ltd, H2 2018
  • Myocardial Infarction - Pipeline by BioCardia Inc, H2 2018
  • Myocardial Infarction - Pipeline by Biscayne Pharmaceuticals Inc, H2 2018
  • Myocardial Infarction - Pipeline by C&C BioPharma LLC, H2 2018
  • Myocardial Infarction - Pipeline by Cadila Healthcare Ltd, H2 2018
  • Myocardial Infarction - Pipeline by Celixir Ltd, H2 2018
  • Myocardial Infarction - Pipeline by CellProthera SAS, H2 2018
  • Myocardial Infarction - Pipeline by CFM Pharma Holding BV, H2 2018
  • Myocardial Infarction - Pipeline by Cynata Therapeutics Ltd, H2 2018
  • Myocardial Infarction - Pipeline by Diffusion Pharmaceuticals Inc, H2 2018
  • Myocardial Infarction - Pipeline by Evotec AG, H2 2018
  • Myocardial Infarction - Pipeline by EyeGene Inc, H2 2018
  • Myocardial Infarction - Pipeline by Faraday Pharmaceuticals Inc, H2 2018
  • Myocardial Infarction - Pipeline by FibroGen Inc, H2 2018
  • Myocardial Infarction - Pipeline by Hemostemix Inc, H2 2018
  • Myocardial Infarction - Pipeline by HUYA Bioscience International LLC, H2 2018
  • Myocardial Infarction - Pipeline by Idorsia Pharmaceutical Ltd, H2 2018
  • Myocardial Infarction - Pipeline by InCarda Therapeutics Inc, H2 2018
  • Myocardial Infarction - Pipeline by Inotrem SA, H2 2018
  • Myocardial Infarction - Pipeline by K-Stemcell Co Ltd, H2 2018
  • Myocardial Infarction - Pipeline by Laboratoires Pierre Fabre SA, H2 2018
  • Myocardial Infarction - Pipeline by Lee's Pharmaceutical Holdings Ltd, H2 2018
  • Myocardial Infarction - Pipeline by LG Chem Ltd, H2 2018
  • Myocardial Infarction - Pipeline by Lonestar Heart Inc, H2 2018
  • Myocardial Infarction - Pipeline by Mesoblast Ltd, H2 2018
  • Myocardial Infarction - Pipeline by MimeTech Srl, H2 2018
  • Myocardial Infarction - Pipeline by New World Laboratories Inc, H2 2018
  • Myocardial Infarction - Pipeline by Nissan Chemical Industries Ltd, H2 2018
  • Myocardial Infarction - Pipeline by Novartis AG, H2 2018
  • Myocardial Infarction - Pipeline by NuvOx Pharma LLC, H2 2018
  • Myocardial Infarction - Pipeline by OMEICOS Therapeutics GmbH, H2 2018
  • Myocardial Infarction - Pipeline by Opsona Therapeutics Ltd, H2 2018
  • Myocardial Infarction - Pipeline by Otsuka Holdings Co Ltd, H2 2018
  • Myocardial Infarction - Pipeline by Quark Pharmaceuticals Inc, H2 2018
  • Myocardial Infarction - Pipeline by Reata Pharmaceuticals Inc, H2 2018
  • Myocardial Infarction - Pipeline by Recardio GmbH, H2 2018
  • Myocardial Infarction - Pipeline by RegeneRx Biopharmaceuticals Inc, H2 2018
  • Myocardial Infarction - Pipeline by Reliance Life Sciences Pvt Ltd, H2 2018
  • Myocardial Infarction - Pipeline by Rubicon Biotechnology Inc, H2 2018
  • Myocardial Infarction - Pipeline by Serodus ASA, H2 2018
  • Myocardial Infarction - Pipeline by Silver Creek Pharmaceuticals Inc, H2 2018
  • Myocardial Infarction - Pipeline by TaiGen Biotechnology Co Ltd, H2 2018
  • Myocardial Infarction - Pipeline by Thrombolytic Science International LLC, H2 2018
  • Myocardial Infarction - Pipeline by TiGenix NV, H2 2018
  • Myocardial Infarction - Pipeline by Vicore Pharma AB, H2 2018
  • Myocardial Infarction - Pipeline by ViroMed Co Ltd, H2 2018
  • Myocardial Infarction - Pipeline by XBiotech Inc, H2 2018
  • Myocardial Infarction - Pipeline by YiChang Humanwell Pharmaceutical Co Ltd, H2 2018
  • Myocardial Infarction - Pipeline by Yuyu Pharma Inc, H2 2018
  • Myocardial Infarction - Dormant Projects, H2 2018
  • Myocardial Infarction - Discontinued Products, H2 2018

List of Figures

  • Number of Products under Development for Myocardial Infarction, H2 2018
  • Number of Products under Development by Companies, H2 2018
  • Number of Products under Development by Universities/Institutes, H2 2018
  • Number of Products by Top 10 Targets, H2 2018
  • Number of Products by Stage and Top 10 Targets, H2 2018
  • Number of Products by Top 10 Mechanism of Actions, H2 2018
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
  • Number of Products by Top 10 Routes of Administration, H2 2018
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2018
  • Number of Products by Top 10 Molecule Types, H2 2018
  • Number of Products by Stage and Top 10 Molecule Types, H2 2018

영문목차

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Myocardial Infarction - Pipeline Review, H2 2018, provides an overview of the Myocardial Infarction (Cardiovascular) pipeline landscape.

Myocardial infarction is the irreversible necrosis of heart muscle secondary to prolonged ischemia. Symptoms include pain, fullness, and/or squeezing sensation of the chest, jaw pain, toothache, headache, shortness of breath, nausea, vomiting, and/or general epigastric discomfort, sweating, heartburn and/or indigestion, arm pain, upper back pain and general malaise (vague feeling of illness).

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Myocardial Infarction - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Myocardial Infarction (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Myocardial Infarction (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Myocardial Infarction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 6, 13, 11, 48, 6 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 2, 19 and 5 molecules, respectively.

Myocardial Infarction (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Myocardial Infarction (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Myocardial Infarction (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Myocardial Infarction (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Myocardial Infarction (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Myocardial Infarction (Cardiovascular)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Myocardial Infarction (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Myocardial Infarction (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Myocardial Infarction - Overview
  • Myocardial Infarction - Therapeutics Development
  • Myocardial Infarction - Therapeutics Assessment
  • Myocardial Infarction - Companies Involved in Therapeutics Development
  • Myocardial Infarction - Drug Profiles
  • Myocardial Infarction - Dormant Projects
  • Myocardial Infarction - Discontinued Products
  • Myocardial Infarction - Product Development Milestones
  • Appendix
Back to Top
아시아 최대 시장정보 제공
전세계에서 발행되고 있는 모든 시장조사보고서를
다루고 있습니다.
사이트에서 검색되지 않는 보고서도 문의 바랍니다.
 
BCC Research